{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:57:15Z","timestamp":1785491835878,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T00:00:00Z","timestamp":1394409600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2369-15-44","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T20:02:11Z","timestamp":1394481731000},"source":"Crossref","is-referenced-by-count":23,"title":["Aldosterone and glomerular filtration \u2013 observations in the general population"],"prefix":"10.1186","volume":"15","author":[{"given":"Anke","family":"Hannemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"V\u00f6lzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlhans","family":"Endlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Wallaschofski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,10]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.ki.5002343","volume":"72","author":"AS Levey","year":"2007","unstructured":"Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007, 72: 247-259. 10.1038\/sj.ki.5002343.","journal-title":"Kidney Int"},{"key":"739_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2458-8-117","volume":"8","author":"QL Zhang","year":"2008","unstructured":"Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008, 8: 117-10.1186\/1471-2458-8-117.","journal-title":"BMC Public Health"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S0272-6386(00)70239-3","volume":"35","author":"MJ Sarnak","year":"2000","unstructured":"Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000, 35: S117-131. 10.1016\/S0272-6386(00)70239-3.","journal-title":"Am J Kidney Dis"},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5551\/jat.10454","volume":"19","author":"T Shoji","year":"2012","unstructured":"Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N, Shirai K, Kashiwagi A: Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb. 2012, 19: 299-315. 10.5551\/jat.10454.","journal-title":"J Atheroscler Thromb"},{"key":"739_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"key":"739_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/eurheartj\/ehr003","volume":"32","author":"LM Ruilope","year":"2011","unstructured":"Ruilope LM, Bakris GL: Renal function and target organ damage in hypertension. Eur Heart J. 2011, 32: 1599-1604. 10.1093\/eurheartj\/ehr003.","journal-title":"Eur Heart J"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","volume":"52","author":"A Whaley-Connell","year":"2010","unstructured":"Whaley-Connell A, Johnson MS, Sowers JR: Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010, 52: 401-409. 10.1016\/j.pcad.2009.12.004.","journal-title":"Prog Cardiovasc Dis"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"JR Sowers","year":"2009","unstructured":"Sowers JR, Whaley-Connell A, Epstein M: Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of internal medicine. 2009, 150: 776-783. 10.7326\/0003-4819-150-11-200906020-00005.","journal-title":"Annals of internal medicine"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1681\/ASN.2007101079","volume":"19","author":"G Remuzzi","year":"2008","unstructured":"Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008, 19: 1459-1462. 10.1681\/ASN.2007101079.","journal-title":"J Am Soc Nephrol"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/s-0029-1243257","volume":"42","author":"M Quinkler","year":"2010","unstructured":"Quinkler M, Born-Frontsberg E, Fourkiotis VG: Comorbidities in primary aldosteronism. Horm Metab Res. 2010, 42: 429-434. 10.1055\/s-0029-1243257.","journal-title":"Horm Metab Res"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1470320310391331","volume":"12","author":"CC Kuo","year":"2011","unstructured":"Kuo CC, Wu VC, Tsai CW, Wu KD: Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2011, 12: 113-122. 10.1177\/1470320310391331.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-12-0899","volume":"168","author":"C Catena","year":"2013","unstructured":"Catena C, Colussi G, Sechi LA: Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol. 2013, 168: C1-5.","journal-title":"Eur J Endocrinol"},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, Beuschlein F, Willenberg HS, Rump LC, Allolio B, Reincke M, Quinkler M: Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol. 2013, 168: 75-81.","journal-title":"Eur J Endocrinol"},{"key":"739_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1681\/ASN.2010010085","volume":"21","author":"CS Fox","year":"2010","unstructured":"Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS: A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010, 21: 2143-2149. 10.1681\/ASN.2010010085.","journal-title":"J Am Soc Nephrol"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1097\/HJH.0b013e328354f65b","volume":"30","author":"S Terata","year":"2012","unstructured":"Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Kanno A, Totsune K, Hoshi H, Satoh H, Sato H, Imai Y: Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the ohasama study. J Hypertens. 2012, 30: 1632-1638. 10.1097\/HJH.0b013e328354f65b.","journal-title":"J Hypertens"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1097\/HJH.0b013e32834bbc8a","volume":"29","author":"JJ Sim","year":"2011","unstructured":"Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar-Zadeh K: Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente southern California cohort. J Hypertens. 2011, 29: 2226-2235. 10.1097\/HJH.0b013e32834bbc8a.","journal-title":"J Hypertens"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ije\/dyp394","volume":"40","author":"H Volzke","year":"2011","unstructured":"Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Junger M, Mayerle J, Kraft M, Lerch MM, Dorr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Glaser S, et al: Cohort profile: the study of health in pomerania. Int J Epidemiol. 2011, 40: 294-307. 10.1093\/ije\/dyp394.","journal-title":"Int J Epidemiol"},{"key":"739_CR18","first-page":"A0828","volume":"11","author":"AS Levey","year":"2000","unstructured":"Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular fi ltration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000, 11: A0828-","journal-title":"J Am Soc Nephrol"},{"key":"739_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139: 137-147. 10.7326\/0003-4819-139-2-200307150-00013.","journal-title":"Ann Intern Med"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ncpneph0362","volume":"3","author":"L Del Vecchio","year":"2007","unstructured":"Del Vecchio L, Procaccio M, Vigano S, Cusi D: Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol. 2007, 3: 42-49. 10.1038\/ncpneph0362.","journal-title":"Nat Clin Pract Nephrol"},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F: Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006, 48: 232-238. 10.1161\/01.HYP.0000230444.01215.6a.","journal-title":"Hypertension"},{"key":"739_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","volume":"33","author":"M Nishimura","year":"1999","unstructured":"Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999, 33: 261-266. 10.1016\/S0272-6386(99)70298-2.","journal-title":"Am J Kidney Dis"},{"key":"739_CR23","first-page":"1801","volume":"13","author":"JM Halimi","year":"1995","unstructured":"Halimi JM, Mimran A: Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995, 13: 1801-1802.","journal-title":"J Hypertens"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M Reincke","year":"2009","unstructured":"Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S: Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009, 94: 869-875. 10.1210\/jc.2008-1851.","journal-title":"J Clin Endocrinol Metab"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008, 93: 3266-3281. 10.1210\/jc.2008-0104.","journal-title":"J Clin Endocrinol Metab"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/MNH.0b013e32833ce6d5","volume":"19","author":"RD Toto","year":"2010","unstructured":"Toto RD: Aldosterone blockade in chronic kidney disease: can it improve outcome?. Curr Opin Nephrol Hypertens. 2010, 19: 444-449. 10.1097\/MNH.0b013e32833ce6d5.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"739_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11906-010-0116-4","volume":"12","author":"Y Lu","year":"2010","unstructured":"Lu Y, Ku E, Campese VM: Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep. 2010, 12: 303-306. 10.1007\/s11906-010-0116-4.","journal-title":"Curr Hypertens Rep"},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"F1013","DOI":"10.1152\/ajprenal.90646.2008","volume":"296","author":"A Whaley-Connell","year":"2009","unstructured":"Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR: Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009, 296: F1013-1022. 10.1152\/ajprenal.90646.2008.","journal-title":"Am J Physiol Renal Physiol"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000209744","volume":"30","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Klemmer PJ: Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol. 2009, 30: 140-146. 10.1159\/000209744.","journal-title":"Am J Nephrol"},{"key":"739_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999, 33: 232-237. 10.1161\/01.HYP.33.1.232.","journal-title":"Hypertension"},{"key":"739_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996, 98: 1063-1068. 10.1172\/JCI118867.","journal-title":"J Clin Invest"},{"key":"739_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","volume":"125","author":"P Rossignol","year":"2012","unstructured":"Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F: Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation. 2012, 125: 271-279. 10.1161\/CIRCULATIONAHA.111.028282.","journal-title":"Circulation"},{"key":"739_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","volume":"26","author":"R Pisoni","year":"2012","unstructured":"Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell\u2019Italia LJ, Cofield SS, Oparil S, Calhoun DA: Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012, 26: 502-506. 10.1038\/jhh.2011.60.","journal-title":"J Hum Hypertens"},{"key":"739_CR34","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"SE Nielsen","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P: Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012, 29: e184-190. 10.1111\/j.1464-5491.2012.03585.x.","journal-title":"Diabet Med"},{"key":"739_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ndt\/gfs429","volume":"28","author":"E Morales","year":"2013","unstructured":"Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutierrez E, Gutierrez-Solis E, Egido J, Praga M: Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant. 2013, 28: 405-412. 10.1093\/ndt\/gfs429.","journal-title":"Nephrol Dial Transplant"},{"key":"739_CR36","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005, 28: 2106-2112. 10.2337\/diacare.28.9.2106.","journal-title":"Diabetes Care"},{"key":"739_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006, 70: 536-542.","journal-title":"Kidney Int"},{"key":"739_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006, 1: 940-951. 10.2215\/CJN.00240106.","journal-title":"Clin J Am Soc Nephrol"},{"key":"739_CR39","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006, 24: 2285-2292. 10.1097\/01.hjh.0000249708.44016.5c.","journal-title":"J Hypertens"},{"key":"739_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006, 1: 256-262. 10.2215\/CJN.01040905.","journal-title":"Clin J Am Soc Nephrol"},{"key":"739_CR41","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009, 20: 2641-2650. 10.1681\/ASN.2009070737.","journal-title":"J Am Soc Nephrol"},{"key":"739_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004, 351: 33-41. 10.1056\/NEJMoa033263.","journal-title":"N Engl J Med"},{"key":"739_CR43","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/ndt\/gfp729","volume":"25","author":"N Halbesma","year":"2010","unstructured":"Halbesma N, Jansen DF, Stolk RP, De Jong PE, Gansevoort RT: Changes in renal risk factors versus renal function outcome during follow-up in a population-based cohort study. Nephrol Dial Transplant. 2010, 25: 1846-1853. 10.1093\/ndt\/gfp729.","journal-title":"Nephrol Dial Transplant"},{"key":"739_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00350.x","volume":"62","author":"FJ Gennari","year":"2002","unstructured":"Gennari FJ, Segal AS: Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int. 2002, 62: 1-9.","journal-title":"Kidney Int"},{"key":"739_CR45","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","volume":"15","author":"DE Weiner","year":"2004","unstructured":"Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004, 15: 1307-1315. 10.1097\/01.ASN.0000123691.46138.E2.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-15-44\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-44","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T23:14:36Z","timestamp":1548198876000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-15-44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-15-44","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,10]]},"article-number":"44"}}